Drug intelligence / Profile preview

HPβCD-I complex

Development stage: Preclinical
Lead developer: Universidade Estadual de Maringá
Modality: Hydrogel Systems → Drug Delivery Systems, Recombinant Proteins and Enzymes
Administration: Topical

Overview

**HPβCD-I complex** is an investigational topical insulin inclusion complex in which insulin is noncovalently complexed with hydroxypropyl-beta-cyclodextrin at a reported 1:5 insulin-to-cyclodextrin molar ratio. The cyclodextrin carrier is intended to improve insulin solubility, stability, and local bioactivity in a Carbopol gel formulation. It was developed at Universidade Estadual de Maringá and evaluated as a once-daily topical gel for healing grade II pressure ulcers in a small randomized, double-blind clinical study.

Other names: HPβCD-Ihydroxypropyl-beta-cyclodextrin-insulin complexinsulin-hydroxypropyl-beta-cyclodextrin inclusion complex

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on HPβCD-I complex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPβCD-I complex.

Explore the full profile